ArticleThe American journal of case reports2026
Acromegaly as the Initial Presentation of Multiple Endocrine Neoplasia Type 1: A Case Report.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Multiple endocrine neoplasia syndrome type 1 (MEN-1) is a rare autosomal-dominant disorder, caused by MEN-1 gene mutations, leading to tumors in multiple endocrine organs, classically the parathyroid glands, the anterior pituitary, and the pancreatic islet cells. Although primary hyperparathyroidism is usually the earliest manifestation, growth hormone-secreting pituitary adenomas rarely present as the initial clinical feature, potentially delaying recognition of the syndrome. CASE REPORT A 34-year-old woman presented with acromegalic features and hypercalcemia. Laboratory testing and magnetic resonance imaging confirmed a recurrent growth hormone-secreting pituitary macroadenoma, and neck imaging identified a parathyroid adenoma. Genetic analysis demonstrated a rare pathogenic variant. After she underwent repeat transsphenoidal surgery, growth hormone and insulin-like growth factor-1 normalized following complete radiological tumor resection. Parathyroid surgery was planned, and the patient was enrolled in multidisciplinary MEN-1 surveillance. CONCLUSIONS The coexistence of a pituitary adenoma and hypercalcemia should prompt evaluation for MEN-1, even in the absence of a family history of the disorder. Early clinical suspicion and recognition enable timely surgical management and structured long-term surveillance, reducing the risk of delayed diagnosis and complications of additional MEN-1-associated tumors. Although MEN-1-associated pituitary adenomas are managed according to the same principles as sporadic tumors, affected patients benefit from multidisciplinary care and lifelong follow-up. Furthermore, reporting rare pathogenic MEN-1 variants contributes to the expanding understanding of genotype-phenotype correlations and the clinical spectrum of this hereditary syndrome. This case highlights that acromegaly may, rarely, represent the first clinical manifestation of MEN-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.